DGAP-News: Mutares AG / Key word(s): Acquisition/Private Equity
mutares AG: mutares AG acquires STADA Production Ireland Ltd. ('SPI')
06.02.2012 / 15:51
---------------------------------------------------------------------
mutares AG, Munich, has taken over STADA Production Ireland Ltd. (SPI), a
contract manufacturer of pharmaceutical drugs based in Clonmel/ Ireland,
from STADA Arzneimittel AG, a German MDAX-listed company on February 06,
2012. SPI generated in 2011 a turnover of approximately EUR 28 million with
production and packaging of tablets and capsules and employs about 180
people.
SPI has been producing drugs in Clonmel since 1984 and holds licenses (FDA,
EU GMP) for the production of a wide range of different pharmaceuticals,
including antibiotics, for the European and the US market. The STADA Group
is selling SPI with the objective to focus its world-wide production
capacities. Based on contract manufacturing agreements SPI will continue
to be a supplier for STADA for a transitional period.
Dr. Axel Geuer, member of the executive board and founder of mutares AG,
says with a view to the future development of the company: 'With a
production capacity of 1.6 million tablets and capsules and a number of
different production methods and packaging techniques SPI is well
positioned to acquire new customers and to further expand its business. We
are looking forward to accompanying this growth strategy.'
mutares AG, Munich (www.mutares.de), acquires midsized companies in whole
and in part, which are sold as a result of a repositioning process at their
owners and which exhibit a clear operational improvement potential. Getting
engaged with its own teams, mutares actively supports its portfolio
companies to generate significant value increase. The focus of the
operational work is to ensure sustainable, long-term growth.
The shares of mutares AG are listed at the Open Market segment of the
Berlin stock exchange (symbol: MUX, ISIN: DE000A0SMSH2).
About STADA Arzneimittel AG:
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad
Vilbel, Germany. STADA's business model focuses on the health care market.
At the center of the internationally oriented business activities are the
pharmaceutical and, in particular, the generics market with sustainable
growth potential. As a globally leading generics producer, STADA has a
traditionally strong presence in Europe and is the clear number 3 in
Germany. In financial year 2010, STADA achieved Group sales of EUR 1,627.0
billion, earnings before interest, taxes, depreciation and amortization
(EBITDA) of EUR 268.8 million and net income of EUR 68.4 million. As of
December 31, 2010, STADA employed a total of 8,024 people.
For further information please contact:
mutares AG
Susanne Staudt
Investor Relations & Corporate Communications
Tel. +49 89 9292776-0
Fax +49 89 9292776-22
info@mutares.de
End of Corporate News
---------------------------------------------------------------------
06.02.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
155433 06.02.2012
DGAP-News: mutares AG: mutares AG acquires STADA Production Ireland Ltd. ('SPI')
| Source: EQS Group AG